Lipocine (NASDAQ:LPCN) Stock Price Passes Above Two Hundred Day Moving Average of $0.00

Lipocine Inc (NASDAQ:LPCN) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.00 and traded as high as $1.93. Lipocine shares last traded at $1.92, with a volume of 2,100 shares.

Separately, HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Lipocine in a research note on Wednesday, May 15th.

The company has a current ratio of 5.37, a quick ratio of 5.37 and a debt-to-equity ratio of 0.49. The business’s 50-day moving average price is $1.68.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.01. As a group, research analysts forecast that Lipocine Inc will post -0.75 earnings per share for the current fiscal year.

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in Lipocine by 4.9% in the third quarter. Vanguard Group Inc. now owns 747,984 shares of the specialty pharmaceutical company’s stock valued at $1,032,000 after purchasing an additional 35,000 shares during the period. Spark Investment Management LLC acquired a new stake in Lipocine in the first quarter valued at about $118,000. Finally, Mercer Global Advisors Inc. ADV acquired a new stake in Lipocine in the first quarter valued at about $256,000. Hedge funds and other institutional investors own 12.49% of the company’s stock.

Lipocine Company Profile (NASDAQ:LPCN)

Lipocine Inc, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability.

See Also: Options Trading – Understanding Strike Price

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.